Trastuzumab rezetecan

Antibody–drug conjugate

Approvedregulatory verdict

Evidence outlook

Approved: Adults with HER2-positive colorectal cancer after failure of oxaliplatin, fluorouracil... (CN)

This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

Also in development:Non-Small Cell Lung Cancer · Phase 3 · investigational in the USHER2-Positive Breast Cancer · Phase 3 · investigational in the USColorectal Cancer · Phase 3 · investigational in the USOvarian Cancer · Phase 3 · investigational in the USGastric Cancer · Phase 3 · investigational in the USBreast Cancer · Phase 3 · investigational in the US · under NMPA review

Also approved (3)
CN
  • Adults with HER2-positive colorectal cancer after failure of oxaliplatin, fluorouracil and irinotecanhengrui.com
  • Adults with locally advanced or metastatic HER2-positive breast cancer who have previously received one or more anti-HER2 therapieshkexnews.hk
  • Adults with unresectable locally advanced or metastatic NSCLC with activating HER2 (ERBB2) mutations who have received at least one prior systemic therapy (reported by NMPA 29 May 2025; one secondary source calls it conditional)1stoncology.com
Product first approved 2025

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (18)
Breast Cancer
NCT07679360 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2026-09-02 – 2032-12 · Triple Negative Breast Cancer
What this study did
NCT06126640 · Jiangsu HengRui Medicine Co., Ltd.
2023-11-20 – 2032-04 · HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
What this study did
NCT07669610 · Fudan University
2026-10-01 – 2029-03-30 · Breast Cancer, Triple Negative Breast Cancer (TNBC)
What this study did
NCT07760844 · Fudan University
2026-10-01 – 2029-03-30 · Breast Cancer, Triple Negative Breast Cancer (TNBC)
What this study did
NCT07111832 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2025-08-20 – 2028-12 · PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer
What this study did
Colorectal Cancer
Gastric Cancer
HER2-Positive Breast Cancer
NCT07196774 · Jiangsu HengRui Medicine Co., Ltd.
2025-10-23 – 2028-12 · Early-stage or Locally Advanced HER2-positive Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT07382687 · Fudan University
2026-02-26 – 2029-12-31 · Breast Cancer
What this study did
Non-Small Cell Lung Cancer
NCT07896005 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2026-12 – 2032-03 · Non Small Cell Lung Cancer
What this study did
Ovarian Cancer
NCT06990503 · Tongji Hospital
2025-06-01 – 2035-06-01 · Ovarian Cancer
What this study did
Other / comorbidity
NCT07118527 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2025-08-18 – 2030-10 · Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma
What this study did
Phase 2 (84)
Breast Cancer
NCT07317778 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2026-02-15 – 2033-09-15 · Breast Cancer Early Stage Breast Cancer (Stage 1-3), HR Positive/HER2 Low Breast Cancer
What this study did
NCT07466303 · Xijing Hospital
2026-03-25 – 2031-04-01 · Breast Cancer, Serplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast Cancer
What this study did
NCT06340230 · Shengjing Hospital
2024-08-23 – 2031-02-28 · HR Positive/HER2 Low Breast Cancer
What this study did
NCT07047755 · Henan Cancer Hospital
2025-07-01 – 2031-02-28 · Breast Cancer
What this study did
NCT07383818 · First Affiliated Hospital of Zhejiang University
2026-02-01 – 2031-02-01 · HR Positive/HER2 Low Breast Cancer
What this study did
NCT07340398 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2025-12-25 – 2031-01-01 · HER2-positive Early Breast Cancer
What this study did
NCT06927180 · Henan Cancer Hospital
2025-04-16 – 2030-12-01 · Breast Cancer Early Stage Breast Cancer (Stage 1-3)
What this study did
NCT05911958 · Henan Cancer Hospital
2023-07-05 – 2029-05-31 · HER2 Low Breast Carcinoma
What this study did
NCT07949695 · Tianjin Medical University Cancer Institute and Hospital
2026-11-01 – 2029-05-31 · HR Positive/HER2 Low Breast Cancer, Neoadjuvant Therapy, SHR-A1811, Toripalimab
What this study did
NCT07618923 · Tang-Du Hospital
2026-06 – 2029-01 · Breast Cancer, HR Positive/HER2 Low Breast Cancer
What this study did
NCT05749588 · Fudan University
2023-03-30 – 2028-12-31 · Triple-negative Breast Cancer
What this study did
NCT06975475 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2025-06-01 – 2028-06-01 · Breast Cancer
What this study did
NCT07305246 · First Hospital of China Medical University
2025-12 – 2027-09 · Breast Cancer
What this study did
NCT05076682 · Fudan University
2022-06-30 – 2027-03-31 · Triple-negative Breast Cancer
What this study did
NCT06592625 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2024-09-20 – 2026-02-28 · Untreated Early-stage or Locally Advanced Breast Cancer
What this study did
Colorectal Cancer
NCT07926477 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2026-12-01 – 2030-12-01 · Colorectal Cancer
What this study did
NCT06666166 · Yunpeng Liu
2024-12 – 2028-12 · Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Colorectal Cancer
What this study did
NCT07796763 · Jiangsu HengRui Medicine Co., Ltd.
2026-11-01 – 2028-11-01 · Advanced Colorectal Cancer Expressing HER2
What this study did
Gastric Cancer
NCT06881017 · China Medical University, China
2025-05-01 – 2029-11-01 · Gastric Cancer, HER2 + Gastric Cancer, CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, PD-L1 Positive
What this study did
NCT07102901 · Jiangsu HengRui Medicine Co., Ltd.
2025-09-05 – 2027-12 · Advanced Gastric Cancer, Metastatic Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT05671822 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2023-03-14 – 2027-12 · HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
What this study did
NCT07110571 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2025-08-28 – 2027-05 · Gastric Cancer, Gastroesophageal-junction Cancer
What this study did
HER2-Positive Breast Cancer
NCT07856303 · Fudan University
2026-10-01 – 2034-08 · HER2-positive Breast Cancer, Early Breast Cancer (EBC)
What this study did
NCT06973525 · Hebei Medical University Fourth Hospital
2025-09-01 – 2032-05-31 · HER2-positive Breast Cancer
What this study did
NCT07766772 · Fujian Cancer Hospital
2026-09-30 – 2031-12-31 · HER2 + Breast Cancer, Advanced Breast Cancer
What this study did
NCT07179939 · Fudan University
2025-09-10 – 2031-12-30 · HER2-positive Breast Cancer
What this study did
NCT07647263 · The First Affiliated Hospital of Soochow University
2026-03-24 – 2031-12 · HER2-positive Breast Cancer
What this study did
NCT07129187 · Chuan Wang
2025-10 – 2030-10 · Early Breast Cancer, HER2 + Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
What this study did
NCT07787338 · First Affiliated Hospital of Zhejiang University
2026-09 – 2030-10 · HER2-positive Breast Cancer
What this study did
NCT07416253 · Henan Cancer Hospital
2026-03 – 2030-07 · Breast Cancer
What this study did
NCT05635487 · Shengjing Hospital
2023-03-16 – 2030-02-28 · HER2-positive Breast Cancer
What this study did
NCT07417241 · Peking University Cancer Hospital & Institute
2026-03-31 – 2029-12-31 · Breast Cancer, HER2-positive Breast Cancer
What this study did
NCT05582499 · Fudan University
2022-11-01 – 2029-09 · Breast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC), HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
What this study did
NCT07528898 · Hebei Medical University Fourth Hospital
2026-05 – 2029-07 · Breast Cancer
What this study did
NCT07132242 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2025-08-30 – 2028-12-31 · Metastatic Breast Cancer With HER2 Positive
What this study did
NCT06361979 · Huihua Xiong
2024-05 – 2026-05 · Breasr Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT07935226 · Harbin Medical University
2026-12-15 – 2032-06-30 · Breast Cancer (Locally Advanced or Metastatic), HR Positive/HER2 Low Breast Cancer
What this study did
NCT07630103 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2026-06 – 2031-12 · Advanced Breast Cancer
What this study did
NCT07203729 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2026-03-01 – 2030-12-30 · HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis
What this study did
NCT07037199 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2025-08-18 – 2030-06-30 · Advanced Breast Cancer
What this study did
NCT07560475 · Tianjin Medical University Cancer Institute and Hospital
2026-06-10 – 2029-12-31 · HER2positive, Advanced Breast Cancer, HER2 + Breast Cancer
What this study did
NCT05769010 · Henan Cancer Hospital
2023-03-31 – 2029-06-30 · Metastatic Breast Cancer
What this study did
NCT07817082 · Tianjin Medical University Cancer Institute and Hospital
2026-09-01 – 2029-03-31 · Advanced Breast Cancer With Ultra-Low HER2 Expression
What this study did
NCT07466927 · Fudan University
2026-03-15 – 2029-01-15 · HER2-negative Breast Cancer
What this study did
NCT07497386 · Jiangsu HengRui Medicine Co., Ltd.
2026-04-28 – 2028-12 · Unresectable Locally Recurrent Breast Cancer, Unresectable Locally Metastatic Breast Cancer
What this study did
NCT07307287 · Tianjin Medical University Cancer Institute and Hospital
2025-12-20 – 2027-12-31 · SHR-A1811, HER2-Postive Breast Cancer, HR+ Breast Cancer, Early Breast Cancer, Locally Advanced Breast Cancer
What this study did
NCT06975462 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2025-06-01 – 2027-12-01 · Breast Cancer Metastatic
What this study did
NCT06433609 · Beijing GoBroad Hospital
2024-08-05 – 2027-11 · Advanced Breast Cancer
What this study did
NCT06649331 · Fudan University
2024-10-21 – 2027-09 · Advanced Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-negative Breast Cancer, Breast Cancer
What this study did
NCT05594095 · Fudan University
2022-12-30 – 2026-12-01 · Breast Neoplasm, Breast Cancer, Hormone Receptor Positive Tumor, HER2-negative Breast Cancer, Advanced Breast Cancer
What this study did
Phase 1/2 (15)
HER2-Positive Breast Cancer
NCT07177950 · Peking University Cancer Hospital & Institute
2025-09-30 – 2029-09-30 · Breast Cancer, Brain Metastases, Leptomeningeal Metastasis
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT06788197 · Henan Cancer Hospital
2025-03 – 2029-03-31 · Breast Cancer, Locally Advanced or Metastatic Breast Cancer
What this study did
NCT06718933 · Fudan University
2025-01-08 – 2027-02-28 · Breast Cancer Metastatic, Breast Cancer Brain Metastases
What this study did
NCT06222879 · Shandong Suncadia Medicine Co., Ltd.
2024-02-20 – 2026-10-31 · Breast Cancer
What this study did
NCT05824325 · Fudan University
2023-03-14 – 2026-10-10 · Breast Cancer
What this study did
NCT05845138 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2023-07-25 – 2025-12-31 · Breast Cancer
What this study did
NCT05792410 · Jiangsu HengRui Medicine Co., Ltd.
2023-04 – 2025-02-27 · HER2 Low Advanced or Metastatic Breast Cancer
What this study did
Non-Small Cell Lung Cancer
NCT05482568 · Jiangsu HengRui Medicine Co., Ltd.
2022-09-15 – 2026-12 · Advanced Non-small Cell Lung Cancer
What this study did
NCT04818333 · Jiangsu HengRui Medicine Co., Ltd.
2021-04-23 – 2025-06 · Advanced Non-small Cell Lung Cancer
What this study did
Ovarian Cancer
NCT06990516 · Tongji Hospital
2025-06-01 – 2035-06-01 · Ovarian Cancer
What this study did
NCT06840002 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2025-03-18 – 2026-12 · Ovarian Cancer
What this study did
Other / comorbidity
NCT07140393 · Jiangsu HengRui Medicine Co., Ltd.
2025-10-28 – 2028-10 · Solid Tumor
What this study did
NCT07231211 · Shanghai Shengdi Pharmaceutical Co., Ltd
2025-11-20 – 2027-12 · Solid Tumors
What this study did
NCT06859775 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2025-04-25 – 2027-01 · Recurrent or Metastatic Cervical Cancer
What this study did
NCT06015048 · Jiangsu HengRui Medicine Co., Ltd.
2023-08-11 – 2026-12-29 · HER2-expressing Advanced Solid Tumors
What this study did
Phase 1 (4)
Colorectal Cancer
NCT04513223 · Jiangsu HengRui Medicine Co., Ltd.
2021-03-30 – 2025-03-28 · Gastric Cancer, Colorectal Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT06710990 · Jiangsu HengRui Medicine Co., Ltd.
2025-02-17 – 2025-10-15 · Advanced Breast Cancer
What this study did
Other / comorbidity
NCT07275242 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2025-12-23 – 2027-12 · Solid Tumor
What this study did
NCT04446260 · Jiangsu HengRui Medicine Co., Ltd.
2020-09-07 – 2025-06-04 · Advanced Solid Tumors
What this study did
Phase 4 (2)
HER2-Positive Breast Cancer
NCT07589699 · The First Affiliated Hospital with Nanjing Medical University
2026-05-31 – 2031-12-31 · Breast Cancer, HER2-positive Breast Cancer, Early-stage Breast Cancer, Locally Advanced Breast Cancer
What this study did
NCT07600164 · Peking University People's Hospital
2026-07-06 – 2031-12-30 · HER2 + Breast Cancer, Advanced Breast Cancer
What this study did
Early phase / not applicable (1)
Non-Small Cell Lung Cancer
NCT07377916 · The First Affiliated Hospital of Guangzhou Medical University
2026-02-15 – 2029-12-31 · Non-Small Cell Lung Cancer
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
HR+/HER2- Metastatic Breast Cancer
NCT07892274 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2026-11-01 – 2031-12-31 · Metastatic Breast Cancer (MBC), HER2-Positive Breast Cancer, Hormone Receptor-Positive Breast Cancer
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (1)
Breast Cancer
NCT07100600 · Henan Cancer Hospital
2025-08-30 – 2032-12-30 · HER2-positive Advanced Breast Cancer, Brain Metastases, Radiotherapy
What this study did

Competitive landscape

This mechanism is crowded: 16 other tracked programmes target it, 4 of them ahead of this one.

This drug's own stage for HER2-Positive Breast Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Trastuzumab Rezetecan: this drugPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Margetuximab (Margenza)ApprovedMonoclonal antibodyHER2not yet gradedNo reviewed efficacy summary in this indication
NeratinibApprovedSmall moleculeEGFR/HER2Reliable signal
NCT00878709: Invasive Disease-free Survival (iDFS) in Neratinib Arm Compared to Placebo Arm at Year 2 (From randomization until time of event up to 2 years): Neratinib 4.7 percentage of participants with events vs Placebo 7.5 percentage of participants with events
Palbociclib (Ibrance)ApprovedSmall moleculeCDK4 and CDK6not yet gradedNo reviewed efficacy summary in this indication
PertuzumabApprovedMonoclonal antibodyHER2/neu Receptor AntagonistReliable signal
NCT01358877: IDFS events, pertuzumab + trastuzumab + chemotherapy vs placebo + trastuzumab + chemotherapy: 7.1% vs 8.7%, hazard ratio 0.81 (95% CI 0.66 to 1.00), p=0.0446 (log-rank); 3-year IDFS event-free rate 94.06% vs 93.24% (CT.gov posted results, data cut-off 19 December 2016).
NCT00567190: IRF-assessed progression-free survival, pertuzumab + trastuzumab + docetaxel vs placebo + trastuzumab + docetaxel: median 18.5 vs 12.4 months, hazard ratio 0.62 (95% CI 0.51 to 0.75), p<0.0001 (stratified log-rank; CT.gov posted results).
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Partial signal
NCT03523585: Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine (Baseline up to 46 months postdose): Trastuzumab Deruxtecan (T-DXd) 17.8 months (95% CI 14.3 to 20.8)
Trastuzumab EmtansineApprovedAntibody–drug conjugateHER2 (ERBB2)Partial signalFeatured results are non-efficacy only in this race
TucatinibApprovedSmall moleculeHER2Reliable signal
NCT05132582: HER2CLIMB-05 (NCT05132582), primary endpoint PFS: median 24.9 months with tucatinib vs 16.3 months with placebo; HR 0.641 (95% CI 0.514-0.799); P<.0001.
NCT03975647: Progression-Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 Based on Investigator Assessment (From the date of randomization to the date of PD or death from any cause or censoring date, whichever occurred first (maximum up to 43 months)): Tucatinib+ Ado-trastuzumab Emtansine 9.5 Months (95% CI 7.4 to 10.9) vs Placebo+ Ado-trastuzumab Emtansine 7.4 Months (95% CI 5.6 to 8.1)
Anbenitamab RepodatecanPhase 3Antibody–drug conjugateHER2 (biparatopic — extracellular domains II and IV)not yet gradedNo reviewed efficacy summary in this indication
Docetaxel (HB1801)Phase 3Small moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
PyrotinibPhase 3Small moleculeEGFR/HER1, HER2, HER4not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab BrengitecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab PamirtecanPhase 3Antibody–drug conjugateHER2Partial signal
NCT06265428: NCT06265428, primary endpoint progression-free survival: BNT323/DB-1303 (trastuzumab pamirtecan) vs T-DM1 met the primary PFS endpoint at a pre-specified interim analysis.
ZanidatamabPhase 3Multispecific antibodyHER2not yet gradedNo reviewed efficacy summary in this indication
BizrolertinibPhase 2/3Small moleculeHER2not yet gradedNo reviewed efficacy summary in this indication
Disitamab VedotinPhase 2/3Antibody–drug conjugateHER2Partial signal
NCT03500380: Median progression-free survival assessed by blinded independent review committee (phase 3 stage, 104 patients randomized): 9.9 months with disitamab vedotin versus 4.9 months with lapatinib plus capecitabine; stratified hazard ratio 0.56 (95.48% CI: 0.35-0.91).
EvorpaceptPhase 2Protein / enzyme therapeuticCD47not yet gradedNo reviewed efficacy summary in this indication
BBO-10203
Phase 1(overall)
Small moleculeRAS:PI3Kα protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
RAD202
Phase 1(overall)
RadiopharmaceuticalHER2
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(94 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Trastuzumab rezetecan to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (7)
November 2026 (1)
Phase 1/2HER2-expressing Advanced Solid TumorsRecruiting
Est. primary completion 2026-11 · NCT06015048 · CT.gov ↗
What to watch
December 2026 (6)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12 · NCT05482568 · CT.gov ↗
What to watch
Phase 1/2Ovarian CancerRecruiting
Est. primary completion 2026-12 · NCT06840002 · CT.gov ↗
What to watch
Phase 2Advanced Salivary Gland CarcinomaActive not recruiting
Est. primary completion 2026-12-30 · NCT05924256 · CT.gov ↗
What to watch
Phase 2HER2 Expression / Amplification in Patients With Biliary Tract CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT06413745 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2026-12-31 · NCT05076682 · CT.gov ↗
What to watch
Phase 3Breast CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT05424835 · CT.gov ↗
What to watch
2027 (27)
March 2027 (4)
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2027-03 · NCT07305246 · CT.gov ↗
What to watch
Phase 2Pancreatic CancerRecruiting
Est. primary completion 2027-03 · NCT06547736 · CT.gov ↗
What to watch
Phase 2HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2027-03 · NCT07416253 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-03 · NCT06433609 · CT.gov ↗
What to watch
April 2027 (2)
Phase 2Biliary Tract Neoplasms ImmunotherapyRecruiting
Est. primary completion 2027-04-15 · NCT07704177 · CT.gov ↗
What to watch
Phase 2Biliary Tract Neoplasms ImmunotherapyRecruiting
Est. primary completion 2027-04-29 · NCT07670273 · CT.gov ↗
What to watch
May 2027 (2)
Phase 3Ovarian CancerRecruiting
Est. primary completion 2027-05 · NCT06828354 · CT.gov ↗
What to watch
Phase 2HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2027-05-31 · NCT06973525 · CT.gov ↗
What to watch
June 2027 (4)
Phase 1Solid TumorRecruiting
Est. primary completion 2027-06 · NCT07275242 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2027-06-01 · NCT06975475 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-06-01 · NCT06975462 · CT.gov ↗
What to watch
Phase 3Gastric CancerRecruiting
Est. primary completion 2027-06-30 · NCT06123494 · CT.gov ↗
What to watch
July 2027 (2)
Phase 2HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2027-07 · NCT07528898 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-07-01 · NCT07630077 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-08-30 · NCT07778745 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2Urachal Cancer, Advanced Solid Tumor Cancer, Antibody-drug ConjugatesRecruiting
Est. primary completion 2027-09-11 · NCT07309770 · CT.gov ↗
What to watch
October 2027 (1)
Phase 1/2Solid TumorRecruiting
Est. primary completion 2027-10 · NCT07140393 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2Biliary Tract Cancer (BTC), First-line TherapyNot yet recruiting
Est. primary completion 2027-11 · NCT07129018 · CT.gov ↗
What to watch
December 2027 (9)
Phase 2Gastric CancerRecruiting
Est. primary completion 2027-12 · NCT07102901 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12 · NCT07281209 · CT.gov ↗
What to watch
Phase 2Gastric CancerRecruiting
Est. primary completion 2027-12 · NCT05671822 · CT.gov ↗
What to watch
Phase 3HER2-Positive Breast CancerActive not recruiting
Est. primary completion 2027-12 · NCT07196774 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT07307287 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT07489703 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT05749588 · CT.gov ↗
What to watch
Phase 2HER2-Positive Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT05582499 · CT.gov ↗
What to watch
Phase 2GC, GEJCNot yet recruiting
Est. primary completion 2027-12-31 · NCT07817654 · CT.gov ↗
What to watch
2028 (34)
January 2028 (2)
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2028-01-15 · NCT07466927 · CT.gov ↗
What to watch
Phase 2mCRC, HER2, Targeted Therapy, Antibody-drug ConjugatesNot yet recruiting
Est. primary completion 2028-01-30 · NCT07355764 · CT.gov ↗
What to watch
February 2028 (2)
Phase 2Breast CancerRecruiting
Est. primary completion 2028-02-01 · NCT07383818 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2028-02-01 · NCT07466303 · CT.gov ↗
What to watch
March 2028 (3)
Phase 3Breast CancerRecruiting
Est. primary completion 2028-03 · NCT07111832 · CT.gov ↗
What to watch
Phase 2Ovarian CancerNot yet recruiting
Est. primary completion 2028-03-30 · NCT07776171 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2028-03-31 · NCT06788197 · CT.gov ↗
What to watch
May 2028 (2)
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2028-05-01 · NCT07796763 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2028-05-31 · NCT07949695 · CT.gov ↗
What to watch
June 2028 (7)
Phase 2HER2-positive Locally Advanced or Metastatic Biliary Tract CancerRecruiting
Est. primary completion 2028-06 · NCT06778031 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-06 · NCT07497386 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2028-06 · NCT07618923 · CT.gov ↗
What to watch
Phase 2Chemotherapy-Induced Nausea and Vomiting (CINV)Recruiting
Est. primary completion 2028-06-01 · NCT07726433 · CT.gov ↗
What to watch
Phase 2Muscle-Invasive Bladder Cancer (MIBC)Active not recruiting
Est. primary completion 2028-06-01 · NCT07624201 · CT.gov ↗
What to watch
Phase 2Muscle-Invasive Bladder Cancer (MIBC), Urinary Bladder CancerNot yet recruiting
Est. primary completion 2028-06-05 · NCT07639983 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-06-30 · NCT07037199 · CT.gov ↗
What to watch
July 2028 (2)
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2028-07 · NCT06666166 · CT.gov ↗
What to watch
Phase 2Urothelial Carcinoma, Advanced Urothelial Carcinoma, Urothelial Carcinoma RecurrentRecruiting
Est. primary completion 2028-07-01 · NCT07241793 · CT.gov ↗
What to watch
August 2028 (2)
Phase 2UTUCRecruiting
Est. primary completion 2028-08-15 · NCT07741448 · CT.gov ↗
What to watch
Phase 2HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2028-08-30 · NCT07132242 · CT.gov ↗
What to watch
September 2028 (5)
Phase 1/2HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2028-09-30 · NCT07177950 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-09-30 · NCT07817082 · CT.gov ↗
What to watch
Phase 2Ovarian CancerNot yet recruiting
Est. primary completion 2028-09-30 · NCT07843303 · CT.gov ↗
What to watch
Phase 3Breast CancerNot yet recruiting
Est. primary completion 2028-09-30 · NCT07669610 · CT.gov ↗
What to watch
Phase 3Breast CancerNot yet recruiting
Est. primary completion 2028-09-30 · NCT07760844 · CT.gov ↗
What to watch
October 2028 (2)
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2028-10-15 · NCT07317778 · CT.gov ↗
What to watch
Phase 2Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) AdenocarcinomaNot yet recruiting
Est. primary completion 2028-10-31 · NCT07912957 · CT.gov ↗
What to watch
December 2028 (7)
Phase 2Muscle-Invasive Bladder Cancer (MIBC)Not yet recruiting
Est. primary completion 2028-12 · NCT07865611 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-12-30 · NCT05769010 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2028-12-31 · NCT07340398 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-12-31 · NCT07631884 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2028-12-31 · NCT07560475 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2028-12-31 · NCT07382687 · CT.gov ↗
What to watch
Phase 4HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2028-12-31 · NCT07589699 · CT.gov ↗
What to watch
2029 (12)
January 2029 (1)
Phase 2HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2029-01-31 · NCT07417241 · CT.gov ↗
What to watch
March 2029 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-03 · NCT07699952 · CT.gov ↗
What to watch
April 2029 (2)
Phase 2HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2029-04 · NCT07787338 · CT.gov ↗
What to watch
Phase 2Gastric Adenocarcinoma and Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2029-04-30 · NCT07802288 · CT.gov ↗
What to watch
May 2029 (1)
Phase 2Breast CancerRecruiting
Est. primary completion 2029-05-01 · NCT06927180 · CT.gov ↗
What to watch
June 2029 (2)
Phase 2HER2-Positive Breast CancerRecruiting
Est. primary completion 2029-06 · NCT07647263 · CT.gov ↗
What to watch
Early phase / not applicableNon-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-06-30 · NCT07377916 · CT.gov ↗
What to watch
August 2029 (2)
Phase 2Gastric CancerNot yet recruiting
Est. primary completion 2029-08-01 · NCT06881017 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-08-30 · NCT07781202 · CT.gov ↗
What to watch
September 2029 (1)
Phase 3Colorectal CancerRecruiting
Est. primary completion 2029-09 · NCT07676162 · CT.gov ↗
What to watch
December 2029 (2)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-12 · NCT07836543 · CT.gov ↗
What to watch
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2029-12-01 · NCT07926477 · CT.gov ↗
What to watch
2030 (8)
April 2030 (1)
Phase 3Breast CancerActive not recruiting
Est. primary completion 2030-04 · NCT06126640 · CT.gov ↗
What to watch
June 2030 (4)
Phase 2Leptomeningeal Metastases, Solid TumorsNot yet recruiting
Est. primary completion 2030-06 · NCT07833657 · CT.gov ↗
What to watch
Phase 1/2Ovarian CancerNot yet recruiting
Est. primary completion 2030-06-01 · NCT06990516 · CT.gov ↗
What to watch
Phase 3Ovarian CancerNot yet recruiting
Est. primary completion 2030-06-01 · NCT06990503 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-06-15 · NCT07203729 · CT.gov ↗
What to watch
October 2030 (1)
Phase 3Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2030-10 · NCT07118527 · CT.gov ↗
What to watch
December 2030 (2)
Phase 3Breast CancerRecruiting
Est. primary completion 2030-12 · NCT07679360 · CT.gov ↗
What to watch
Phase 2HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2030-12-30 · NCT07179939 · CT.gov ↗
What to watch
2031 (5)
February 2031 (1)
Phase 3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2031-02 · NCT07896005 · CT.gov ↗
What to watch
June 2031 (1)
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2031-06 · NCT07630103 · CT.gov ↗
What to watch
December 2031 (3)
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2031-12-15 · NCT07935226 · CT.gov ↗
What to watch
Phase 4HER2-Positive Breast CancerRecruiting
Est. primary completion 2031-12-30 · NCT07600164 · CT.gov ↗
What to watch
Phase 2HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2031-12-31 · NCT07766772 · CT.gov ↗
What to watch
2032 (1)
August 2032 (1)
Phase 2HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2032-08 · NCT07856303 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

2 July 2026Filing acceptedNMPA accepts the marketing application for trastuzumab rezetecan in HER2-low breast cancer (CXSS2600103), with priority review
China, NMPA · Jiangsu Hengrui Pharmaceuticals · Source ↗